A previous study conducted on patient-derived LCLs indicated Regulator of G protein signaling 2 (RGS2) mRNA levels as a potential biomarker for AD, showing (by a data mining approach) lower RGS2 mRNA levels in AD patients compared to non-aged-matched controls in several brain regions and blood (Hadar et al., 2016). The gene discussed is RGS2; the disease is Alzheimer disease.